Role of HGF/MET axis in resistance of lung cancer to contemporary management

Medicine & Life Sciences

• Hepatocyte Growth Factor 100%
• Lung Neoplasms 66%
• ErbB Receptors 21%
• Proto-Oncogenes 17%
• Phosphatidylinositol 3-Kinases 15%
• Transcriptional Activation 13%
• Therapeutics 13%
• Drug Therapy 13%
• Vascular Endothelial Growth Factor A 13%
• Apoptosis Inducing Factor 10%
• Growth Inhibitors 9%
• Taxoids 9%
• Cetuximab 9%
• Apoptosis 9%
• Vascular Endothelial Growth Factor Receptor 9%
• Gene Amplification 8%
• Anthracyclines 8%
• Survival 8%
• MAP Kinase Signaling System 8%
• Platinum 8%
• Epithelial-Mesenchymal Transition 7%
• Phosphatidylinositol 3-Kinase 7%
• Mitogen-Activated Protein Kinases 7%
• Neoplasms 7%
• Non-Small Cell Lung Carcinoma 6%
• DNA Damage 6%
• Histology 6%
• Hypoxia 6%
• Carcinogenesis 5%
• Radiation 5%
• Ligands 5%
• Radiotherapy 5%
• Cell Proliferation 5%
• Phenotype 4%
• Gene Expression 4%
• Mortality 3%
• Genes 3%